REPL

AI Memo

Replimune Group

As of 2026-05-23/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-23 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FDA issues second Complete Response Letter for RP1 BLA • 2026-04-10

Expected move: -42%

Biggest risk

A second CRL materially lowers near-term approval visibility, extends regulatory delay risk, and leaves the name exposed to further downside if FDA requirements are onerous, unclear, or require additional clinical work.

Invalidation

Break below $2 or thesis failure.

What would change my mind?

A recovery case depends on Replimune producing a credible FDA path for RP1 after the second CRL. The packet still shows a $13.00 median target, but analyst count and post-CRL revision detail are unavailable, so that target should not be treated as fresh confirmation.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-23

Base target

p=45%

Bull target

$13

p=20%

Bear target

p=35%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

RP1 regulatory-path clarification remains the main monitoring item
A recovery case depends on Replimune producing a credible FDA path for RP1 after the second CRL.
The packet still shows a $13.00 median target, but analyst count and post-CRL revision detail are unavailable, so that target should not be treated as fresh confirmation.

BearKey bullets

Low-coverage small-cap biotech with no fresh analyst revisions in the packet; valuation anchors may be stale after the regulatory setback.
Peer set is broad same-sector market-cap context rather than direct operating comparables, limiting relative-valuation confidence.
Potential delay to any commercial launch in advanced melanoma if additional FDA work, a resubmission, or revised regulatory strategy is required.

WatchKey bullets

FDA issues second Complete Response Letter for RP1 BLA

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=45%)

Bull/Bear spread: +50% / -77%

Vs latest close: Bull +50% · Base -42% · Bear -77%

Scenario probabilities

Bull Target: $13 (p=20%)Base Target: $5 (p=45%)Bear Target: $2 (p=35%)

Commentary

Primary-source evidence confirms the second FDA CRL on April 10, 2026, and the packet's secondary coverage described a sharp post-news selloff. The current anchor price of $4.91 remains far below the packet's $13.00 median target, but analyst revision data are absent, social context is unavailable, and coverage is thin. This should be read as a low-conviction monitoring view focused on regulatory-path clarification rather than a catalyst-driven call.

As of 2026-05-23 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

RP1 regulatory-path clarification remains the main monitoring item

Scenarios

Bull Target (Scenario probability)

$13 / p=20% prob

Base Target (Scenario probability)

$5 / p=45% prob

Bear Target (Scenario probability)

$2 / p=35% prob

Price $9 as of 2026-05-29

Nearest Scenario: Base (∆ 42%)

Targets vs latest close: Bull +50% · Base -42% · Bear -77%

Sentiment & Exposure

News Sentiment (30d)

-0.80

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-04-10
FDA issues second Complete Response Letter for RP1 BLA
Replimune disclosed in its April 13, 2026 8-K that on April 10, 2026 it received a second Complete Response Letter from the FDA for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma. This is the dominant thesis-resetting event; the packet's secondary coverage described a severe share-price reaction, but the primary source does not provide a resolved forward timeline. [#8-K-2026-04-13]
Prob 100.00% • Move -64.00% • Priced-in 100.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

RP1 regulatory-path clarification remains the main monitoring item
2027-05-23
After the second CRL, the key forward-looking company-specific monitor is whether Replimune discloses a credible FDA interaction, resubmission path, or required additional work for RP1 in advanced melanoma. The available primary-source evidence confirms the CRL but does not establish timing, requirements, or likelihood of a successful resubmission, so this is a low-conviction monitoring catalyst rather than a firm event date. [#8-K-2026-04-13]
Prob 35% • Move 25% • Priced-in 40%

Risks

Low-coverage small-cap biotech with no fresh analyst revisions in the packet; valuation anchors may be stale after the regulatory setback.
Peer set is broad same-sector market-cap context rather than direct operating comparables, limiting relative-valuation confidence.
Potential delay to any commercial launch in advanced melanoma if additional FDA work, a resubmission, or revised regulatory strategy is required.
Second FDA Complete Response Letter keeps the RP1 approval path unresolved and materially increases regulatory risk.

Peers

Symbol	Summary
ADCT	Same-sector small-cap biotech peer used only for size and event-volatility context; the packet does not establish it as a direct operating comparable.
NGNE	Same-sector small-cap biotech peer used as a market-cap and clinical-stage volatility reference; direct product or indication overlap is not supported by the packet.
SGMT	Same-sector small-cap biotech peer used for broad relative context; not a direct RP1 or melanoma-program comparable from the available evidence.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-23

AI Stock Memo: REPL - Replimune Group - RankAlpha